XCancer

Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Description:

RATIONALE: Diagnostic procedures, such as positron emission tomography, using the drug fluorine F18-EF5 to find oxygen and fludeoxyglucose F18 to find sugar in tumor cells may help in planning treatment for patients with non-small cell lung cancer.

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Phase:

Phase 1

Government Study Link:

NCT01017133 - Click here to see study on

ClinicalTrials.gov

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

EF5

Isotope(s):
Target(s):
  • Hypoxia
Ligand Class: Small Molecules
Inclusion
  • * Subjects must have a histologically confirmed NSCLC or clinical and imaging evidence of a de novo mass that is likely to be a NSCLC, stage I, II, or IIIA, for which surgery would be indicated for routine medical indications
  • WBC \> 2,000/mm\^3
  • Platelet count \> 100,000/mm\^3
  • ECOG performance status between 0 and 2
Exclusion
  • Uncontrolled intercurrent illness that would limit compliance with study requirements
  • Subjects who have been treated with neoadjuvant radiation or chemotherapy prior to their biopsy or excision are excluded because the impact of these therapies upon the degree of hypoxia of the tumor is unknown